Avella Specialty Pharmacy joins limited distribution network for Imbruvica

FDA approved drug, marketed by Pharmacyclics and J&J subsidiary Janssen Biotech, earlier this week

PHOENIX — Drug makers Johnson & Johnson and Pharmacyclics have added Avella Specialty Pharmacy to their limited-distribution network for a newly approved blood cancer drug.

Avella said Thursday that it had joined the limited-distribution network for Imbruvica (ibrutinib), which the Food and Drug Administration approved this week for mantle cell lymphoma. Avella is one of five specialty pharmacies to join the network, the company said.

"We are proud to be a specialty pharmacy provider of Imbruvica capsules, now approved by the FDA for the treatment of patients with MCL," Avella VP business development Leslie Yendro said. "Avella has the ability to serve patients in all 50 states and to provide high-touch patient services and reliable product data to ensure maximum drug effectiveness."


Login or Register to post a comment.